Healthcare Equipment and Supplies
Company Overview of ACell, Inc.
ACell, Inc. engages in the development and commercialization of extracellular matrix devices to repair and remodel damaged tissues and organs in a range of surgical procedures for the U.S. and international patents. It offers MatriStem technology, a non-crosslinked, resorbable, and acellular material; MatriStem Wound Care Matrix, a wound care device with regenerative medicine technology; MatriStem Plastic Surgery Matrix, a plastic surgery and wound care device; MatriStem Hernia Matrix, a general surgery device; and Cytal Wound Matrix 3-Layer and Cytal Wound Matrix 6-Layer that are wound management devices for the management of partial- and full-thickness wounds, including pressure ulcers, ve...
6640 Eli Whitney Drive
Columbia, MD 21046
Founded in 1999
Key Executives for ACell, Inc.
Chief Executive Officer and President
Vice President of Operations
Senior Vice President and General Counsel
Vice President of Product Development
Compensation as of Fiscal Year 2016.
ACell, Inc. Key Developments
ACell, Inc. Names Brad Adams as Vice President of Sales
Aug 22 16
ACell, Inc. announced that it has named Brad Adams Vice President of Sales. He will be responsible for directing the strategy and execution of both field sales and national accounts. Adams has more than 20 years of senior healthcare management experience. Most recently, he served as Executive Vice President, Commercial for Smith & Nephew, Inc. Prior to Smith & Nephew, Adams was Vice President of Sales for Healthpoint Biotherapeutics, Inc. and previously served as Vice President of Worldwide Sales for two Johnson & Johnson companies: Animas, Inc. and Therakos, Inc.
ACell, Inc. Receives FDA Clearance for Concurrent Use of its Wound Management Devices
Mar 23 16
ACell, Inc. announced that it has received additional FDA clearance for its MicroMatrix device, which describes the concurrent use of MicroMatrix in conjunction with CytalTM Wound Matrix or Cytal Burn Matrix devices. MicroMatrix, the micronized particulate form of ACell's patented Urinary Bladder Matrix (UBM) technology, facilitates coverage of the wound bed, especially in irregular wounds. Cytal Wound Matrix (1-Layer, 2-Layer, 3-Layer and 6-Layer) and Cytal Burn Matrix are sheet forms of UBM and provide a robust scaffold for cell infiltration and host tissue deposition. This latest FDA clearance also provides for the modification of the MicroMatrix Instructions for Use to include the option for hydration of the device in sterile saline prior to application, in order to facilitate ease of use and adherence to the wound bed. MicroMatrix and Cytal Matrix devices are intended for use in various wound management applications. ACell also manufactures a distinct line of surgical products, based upon the same UBM technology.
ACell, Inc. Announces Management Changes
Jan 11 16
ACell, Inc. announced that it has named Patrick (Pat) McBrayer as President and Chief Executive Officer. McBrayer succeeds Kyle Kerbawy, who will remain as Chairman of the Board. McBrayer has more than 20 years of healthcare senior management experience. He currently serves on the Board of Directors of Misonix, Inc. and was President and CEO of AxioMed Spine Corporation until the company was acquired in 2014. McBrayer is on the Board of Directors of Misonix Inc. He has recently advised medical device companies in spine, orthopedics and biotechnology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|